Tekla Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Tekla Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-162,599	Closed	-$1.63M	–	170
2022 Q2	$1.63M	Hold	162,599	–	–	0.06%	119
2022 Q1	$2.01M	Hold	162,599	–	–	0.07%	124
2021 Q4	$3.72M	Sell	162,599 -90,222	-36%	-$2.14M	0.12%	110
2021 Q3	$5.59M	Sell	252,821 -145,099	-36%	-$2.3M	0.18%	101
2021 Q2	$5.16M	Hold	397,920	–	–	0.17%	116
2021 Q1	$5.17M	Buy	397,920 +97,309	+32%	+$1.41M	0.18%	115
2020 Q4	$4.16M	Hold	300,611	–	–	0.15%	126
2020 Q3	$4.43M	Buy	300,611 +209,823	+231%	+$3.04M	0.17%	110
2020 Q2	$1.48M	Hold	90,788	–	–	0.06%	179
2020 Q1	$1.32M	Hold	90,788	–	–	0.06%	158
2019 Q4	$1.84M	Buy	+90,788	New	+$836K	0.07%	156

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tekla Capital Management's AUPH Position: Q3 2022 in Review

Tekla Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2022, closing a stake of 162,599 shares — an estimated $1.63M sold.

Tekla Capital Management first reported a position in AUPH in Q4 2019 and held it in 11 quarters. The position peaked at $5.59M in Q3 2021. 189 funds tracked by Wall St. Rank hold AUPH as of Q3 2022.

Tekla Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Tekla Capital Management sold 162,599 Aurinia Pharmaceuticals shares in Q3 2022, an estimated $1.63M.
Tekla Capital Management first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 11 quarters.
Tekla Capital Management's Aurinia Pharmaceuticals position peaked at $5.59M in Q3 2021.
189 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2022.

Based on Tekla Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.